← Eichor
Condition: Myelodysplastic Syndromes Adult Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Myelodysplastic Syndromes Adult

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelod
Phase 3 · 62 location(s) · Institut de Recherches Internationales Servier · NCT06465953Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Phase 1 · 2 location(s) · Remedy Plan, Inc. · NCT07107126A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS
Phase 3 · 179 location(s) · Takeda · NCT06499285A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1 · 2 location(s) · Shanghai Lanyi Therapeutics Co., Ltd. · NCT07256301Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Yo
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06756152Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-
Phase 3 · 91 location(s) · University of Ulm · NCT04628026Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Phase 1 · 1 location(s) · Immune System Key Ltd · NCT04365179Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysp
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02115295Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
Phase N/A · 8 location(s) · Dana-Farber Cancer Institute · NCT04968834Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Phase 2 · 3 location(s) · Children's Hospital of Philadelphia · NCT05194397A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combine
Phase 2 · 2 location(s) · Franziska Wachter · NCT05796570Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
Phase 1/Phase 2 · 1 location(s) · Haukeland University Hospital · NCT06199557Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
Phase 2 · 1 location(s) · University Hospital, Akershus · NCT05025098Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
Phase 3 · 2 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06829472Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Pati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00801489Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT068023153'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Phase 1 · 13 location(s) · BlossomHill Therapeutics · NCT06501196Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 · 5 location(s) · Andrew E. Place, MD · NCT05292664A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
NA · 1 location(s) · Ruijin Hospital · NCT06329999
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.